novo nordisk semaglutide patent fee canada The semaglutide story: highlighting the need to maintain patent protection in Ozempic's Patent Protection Starts to

Our new report tracks how the markets will behave in US, UK, Germany, Japan, and 40 countries

Understanding the facts behind this potential side effect is essential for anyone considering GLP-1 therapy

In nearly every sample, the medication was undetectable

Research published in peer-reviewed medical journals has helped shape how the medical community understands the potential of multi-receptor weight-loss medications

Standard of Care) study for alogliptin (58, 62), the Savor-TIMI-53 study (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes MellitusThrombolysis in Myocardial Infarction 53) for saxagliptin (60, 63), the TECOS study (Trial Evaluating Cardiovascular Outcomes With Sitagliptin) for sitagliptin (59, 64) and the CARMELINA study (Cardiovascular safety and Clinical Outcome with Linagliptin) for linagliptin (61, 65)

A Blue Cross Blue Shield analysis of insurance records from 2014 to 2023 found that about half of those prescribed a GLP-1 agonist stopped taking it within 12 weeks